SCHEMBL4720151

SCHEMBL4720151

CCOc1s[c]nc1-c1cccc2ccccc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ENPP1 P22413 1/20 0.39
S1PR1 P21453 1/20 0.39
S1PR3 Q99500 1/20 0.39
FDPS P14324 1/20 0.38
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
POLB P06746 1/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
TSHR P16473 1/20 0.36
BCHE P06276 1/20 0.35
CHRNB4 P30926 1/20 0.35
CHRNA3 P32297 1/20 0.35
CHRNA7 P36544 1/20 0.35
GUSB P08236 1/20 0.35
PGK1 P00558 1/20 0.35
ALDH1A1 P00352 2/20 0.34
HTR2C P28335 2/20 0.34
PPARG P37231 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4724445 0.89 CNR1 (0.37) ENPP1MEN1KMT2AMAPTHPGD
SCHEMBL4765519 0.88 HTR1B (0.39) L3MBTL1CHRNB4CHRNA3CHRNA7ALDH1A1
SCHEMBL4720658 0.84 PGK1 (0.37) MEN1KMT2AL3MBTL1POLBMAPT
SCHEMBL4720883 0.77 TTK (0.40) MEN1KMT2AMAPTHPGDALDH1A1
SCHEMBL4764109 0.72 ENPP1 (0.39) ENPP1S1PR1S1PR3FDPSMEN1
SCHEMBL4720960 0.72 ENPP1 (0.42) ENPP1S1PR1S1PR3FDPSMEN1
SCHEMBL4723619 0.72 ENPP1 (0.39) ENPP1S1PR1S1PR3FDPSMEN1
SCHEMBL8543656 0.72 ALDH1A1 (0.43) MEN1KMT2AL3MBTL1MAPTHPGD
SCHEMBL4724523 0.71 S1PR1 (0.44) ENPP1S1PR1S1PR3FDPSMEN1
SCHEMBL4720245 0.68 S1PR1 (0.45) ENPP1S1PR1S1PR3FDPSMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors PFIZER INC. 2008-07-24 US disclosed
EP-1874780-A1 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2008-01-09 EP disclosed
WO-2006100591-A1 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors TBXA2R, P2RY4, PF4 ENPP1 414/4885S1PR1 618/4885S1PR3 346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.